Register
FDA Panel: Thumbs Up for Cefiderocol in Urinary Tract Infections |
News and Updates
eMediNexus Coverage from: 
FDA Panel: Thumbs Up for Cefiderocol in Urinary Tract Infections
eMediNexus,  17 October 2019
remove_red_eye 544 Views
#Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Urology

1 Read Comments                

An FDA advisory panel voted 14-2 to recommend approval for cefiderocol, a novel antibiotic for complicated urinary tract infections (cUTI), including pyelonephritis, in patients with limited or no other treatment options.

While members of the FDAs Antimicrobial Drugs Advisory Committee were mostly impressed by the data submitted for the drug, they raised concern about a mortality imbalance disfavoring cefiderocol in the CREDIBLE-CR study, which compared the drug to best available therapy in patients with a variety of carbapenem-resistant infections… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now